Renaissance Technologies LLC Purchases 52,502 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Renaissance Technologies LLC raised its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 52.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 152,702 shares of the biotechnology company’s stock after buying an additional 52,502 shares during the quarter. Renaissance Technologies LLC’s holdings in AnaptysBio were worth $3,827,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ANAB. Allspring Global Investments Holdings LLC acquired a new stake in shares of AnaptysBio in the first quarter valued at about $38,000. Headlands Technologies LLC grew its stake in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 2,900 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in AnaptysBio by 66.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 2,051 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of AnaptysBio during the 1st quarter worth approximately $222,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of AnaptysBio during the 1st quarter worth approximately $265,000.

Insider Activity

In other news, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the transaction, the insider now owns 11,618 shares in the company, valued at approximately $406,630. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,940 shares of company stock valued at $1,251,836. 33.70% of the stock is currently owned by insiders.

AnaptysBio Trading Down 2.0 %

AnaptysBio stock opened at $31.87 on Friday. The firm’s 50 day simple moving average is $35.68 and its 200 day simple moving average is $28.15. AnaptysBio, Inc. has a 1-year low of $13.36 and a 1-year high of $41.31. The firm has a market capitalization of $870.66 million, a PE ratio of -5.19 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The company had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. Research analysts forecast that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ANAB. JPMorgan Chase & Co. lifted their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Truist Financial boosted their price target on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of AnaptysBio in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research note on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average target price of $51.10.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.